Schrödinger (SDGR)
Builds physics-based software for molecular design and uses it in drug discovery.
Something off on this page? Send us feedback.
Sells physics-based molecular modeling software to life-science and materials-science researchers, then applies the same platform to proprietary and partnered therapeutics. Software is the larger segment, while drug discovery revenue depends on collaborations, milestones, royalties, and clinical execution.
Provides a physics-based molecular discovery platform for life-science and materials-science R&D. Software products include LiveDesign for collaboration, Maestro for modeling workflows, FEP+ for binding predictions, and Glide for docking and screening.
Applies the same computational platform inside a therapeutics group that advances proprietary programs and partnered drug discovery work. Revenue comes from software licenses and drug discovery economics such as upfront payments, milestones, royalties, and collaborator equity stakes.
Serves biopharmaceutical companies, industrial customers, academic institutions, and government laboratories worldwide. The business depends on life-sciences R&D budgets, collaboration outcomes, clinical execution, and competition from commercial vendors, academic packages, in-house biopharma tools, and AI-enabled discovery companies.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 14, 2026 | UBS | Initiate | Rating: —Target: $18 | Target: $19 |
| Jan 7, 2026 | UBS | Target | Target: — | Target: $18 |
| Dec 15, 2025 | B of A Securities | Upgrade | ||
| Sep 29, 2025 | Goldman Sachs | Target | Target: $27 | Target: $19 |
| Aug 15, 2025 | Citigroup | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $413.7M · Total debt $108.0M · Total assets $640.4M · Shareholders' equity $329.0M
- Revenue
- $58.9M
- Operating income
- −$41.5M
- Net income
- $6.0M
No dividends on record.
| Institutions | 174.64% | 130.64M shares | |
|---|---|---|---|
| 244 holders · as of Jun 30, 2026 | |||
| Insiders | 2.32% | 1.73M shares | |
| 20 holders · as of Sep 21, 2026 | |||
| Adds to | 176.96% | ||
74.81M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 176.96%; nothing is left for Other.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 28.13% | 10.52M · 10.52M | as of Jun 30, 2026 |
Bill & Melinda Gates Foundation TrustInstitution | 18.67% | 6.98M · 6.98M | as of Jun 30, 2026 |
Rubric Capital Management LPInstitution | 17.11% | 6.40M · 6.40M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 10.13% | 3.79M · 3.79M | as of Jun 30, 2026 |
Nikko Asset Management Americas, Inc.Institution | 7.24% | 2.71M · 2.71M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 17, 2026 | Karen Akinsanya | officer: See Remarks | −31,599 | $29.37 |
| Jul 16, 2026 | Rachit Jain | officer: EVP & CFO | −875 | $15.60 |
| Apr 16, 2026 | Rachit Jain | officer: EVP & CFO | −844 | $12.75 |
| Apr 17, 2026 | Ramy Farid | director, officer: President & CEO | −43,000 | $12.21 |
| Apr 16, 2026 | Ramy Farid | director, officer: President & CEO | −43,000 | $12.33 |
- Cadence Design Systems
OpenEye overlaps in cloud molecular design and docking
- Certara
Model-informed drug development software and services
- Revvity
Signals software overlaps in R&D informatics and chemistry
- Simulations Plus
ADMET and PBPK modeling in model-informed drug R&D
- AbCellera Biologics
Antibody discovery platform and partner economics
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Schrödinger | $31.00 | +0.98% | $2.26B | — | — | 8.7 | +7.5% |
| Cadence Design Systems | $302.67 | −0.04% | $81.21B | 58.6 | 35.3 | 13.9 | +24.2% |
| Certara | $8.83 | −0.11% | $1.33B | — | 22.8 | 3.2 | −10.8% |
| Revvity | $143.31 | 0.00% | $16.02B | 68.4 | 25.5 | 5.5 | −1.3% |
| Simulations Plus | $18.41 | 0.00% | $372.7M | 46.1 | 21.7 | 4.5 | +7.5% |
| AbCellera Biologics | $12.71 | +0.53% | $3.87B | — | — | 58.4 | −76.3% |
| Median | 58.6 | 24.1 | 5.5 | −1.3% |